Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy

Viatris Inc. has received approval from Japan's Ministry of Health, Labour and Welfare for its drug WAKIX (pitolisant) to treat excessive daytime sleepiness linked to obstructive sleep apnea and narcolepsy. This marks the first approval of a histamine H3 receptor antagonist/inverse agonist for these conditions in Japan, addressing a significant unmet medical need and enhancing Viatris' innovative portfolio in the region.